| Name | Title | Contact Details |
|---|
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.
We empower the most underserved stakeholder in the healthcare system – the family caregiver. While training programs exist for home health aides or nurses to help manage care of the elderly, family members, who provide 80%+ of care to loved ones aging-in-place, have limited access to training. For example, actionable education like how to prevent falls in the house, safely transfer from a bed or chair, or manage difficult behaviour when a loved one has dementia. Recognizing that this content exists but isn`t available to families, Trualta adapted professional-level healthcare training for the family member audience. We deliver the training via an informal and interactive online learning environment, and tailor the learning to each caregiver`s situation. The program incentivizes engagement with a rewards system, and users can redeem rewards for helpful products and services. Our customers, healthcare payers and providers in Canada & the US, offer Trualta at point-of-care to better enable families to transition aging loved ones from hospital to home, and sustain independent living. Through clinical validation studies in the US and Canada, we are linking participation in Trualta`s program to improved outcomes and reduced costs. We are a proud resident company of the Biomedical Zone in downtown Toronto and the Invest Ottawa Accelerator program. If you are passionate about educating and enabling families to improve care for our aging population, drop us a note at info@trualta.com – we`d love to hear from you.
Medical Card System, Inc. (MCS) is a San Juan, PR-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
GeneSolve is the world’s first dedicated body chemistry company, with offices in the San Francisco Bay Area and Dallas, Texas. GeneSolve doctors utilize extensive laboratory tests and genetic analysis to provide personalized preventative health care programs to individual patients, as well as to groups through corporate wellness programs.
Simplex Diabetic Supply Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Brentwood, TN. To find more information about Simplex Diabetic Supply Inc., please visit www.simplexdiabetes.com